Vaxxas
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$15.0m | Series A | ||
$25.0m | Series B | ||
AUD50.0k | Grant | ||
AUD50.0k | Grant | ||
$5.0m | Grant | ||
* | $22.0m | Grant | |
* | $23.0m | Late VC | |
* | $4.3m | Grant | |
* | AUD4.0m | Grant | |
Total Funding | $97.0m |
Related Content
Recent News about Vaxxas
EditVaxxas is a pioneering company in the biotechnology sector, focused on revolutionizing the way vaccines are delivered. The company has developed a novel, needle-free vaccination technology that significantly improves the efficacy and performance of both existing and next-generation vaccines. Vaxxas primarily serves healthcare providers, pharmaceutical companies, and global health organizations. Operating in the global healthcare market, Vaxxas employs a business model that includes partnerships, licensing agreements, and direct sales to generate revenue. By collaborating with renowned organizations, Vaxxas maximizes the impact of its technology on a global scale. The company's innovative approach aims to create a healthier world by making vaccinations more effective and accessible.
Keywords: biotechnology, needle-free, vaccines, healthcare, efficacy, innovation, partnerships, licensing, global health, technology.